Frontiers in Oncology (Mar 2021)

Peripheral Blood Genetic Biomarkers for the Early Diagnosis of Hepatocellular Carcinoma

  • Ting Song,
  • Ting Song,
  • Ting Song,
  • Li Li,
  • Li Li,
  • Shaobo Wu,
  • Yan Liu,
  • Yan Liu,
  • Caiping Guo,
  • Wen Wang,
  • Lili Dai,
  • Tong Zhang,
  • Tong Zhang,
  • Hao Wu,
  • Hao Wu,
  • Bin Su,
  • Bin Su

DOI
https://doi.org/10.3389/fonc.2021.583714
Journal volume & issue
Vol. 11

Abstract

Read online

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and has high mortality. Biomarkers related to HCC, such as alpha-fetoprotein, and imaging technology, such as ultrasound and computed tomography, have been used to screen and monitor HCC, but HCC is still difficult to diagnose effectively in the early stage due to the low sensitivity of the above mentioned traditional methods. There is an urgent need for noninvasive biomarkers to facilitate the screening and early diagnosis of HCC. With the advancement of next-generation sequencing, genetic biomarkers are becoming the core of cancer diagnosis. Genetic biomarkers such as peripheral blood circulating tumor DNA, microRNAs, long noncoding RNAs, circular RNAs, and exosomes have become the focus of early HCC diagnostics. HCC genetic biomarkers have been implemented in clinical practice. In this review, we describe the available literature on peripheral blood genetic biomarkers in the diagnosis of early HCC.

Keywords